Primary treatment of patients with MDS/MPN with neutrophilia in the Netherlands, from 2001 to 2019. (A) The results of primary therapy in broad categories are shown according to age at diagnosis and calendar period of diagnosis for patients diagnosed during the calendar period 2001 to 2019 (N = 347). The absolute number of patients within a specific calendar period and age group is shown above the bar. (B) The specific type of primary therapy according to age at diagnosis are shown for patients diagnosed during the calendar period 2014 to 2019 (N = 110). The absolute number of patients within a specific age group is shown above the graph bar. For both panels, the absolute number of patients with a specific treatment group is shown in the bar when space allows for readability. Of the 10 patients who received intensive chemotherapy, 8 (80%) were consolidated with an alloHSCT (7 in patients aged ≤65 years and 1 in a patient aged >65 years). One patient received an alloHSCT after treatment with imatinib. Lastly, 6 patients received an upfront alloHSCT (4 in-patients aged ≤65 years and 2 in-patients aged >65 years). Four patients, all aged >65, received treatment with a hypomethylating agent, of whom 3 received azacitidine and 1 received decitabine. Nine patients received treatment with a targeted agent, of whom 4 received dasatinib (1 in a patient aged ≤65 years and 3 in patients aged >65 years), 3 received imatinib (all in those aged >65 years), and 2 received ruxolitinib (1 in each age group). HMA, hypomethylating agent; HU, hydroxyurea; TKI, tyrosine kinase inhibitor.